PRISM BioLab is a biotechnology company that specializes in drug discovery using its proprietary PepMetics® Technology to create peptides that mimic α-helix or β-turn structures.

PRISM BioLab

PRISM BioLab is committed to maximizing the potential of its PepMetics™ Technology, transforming the “undruggable” to “druggable” with the aim of finding cures for the incurable.

PRISM BioLab is a biotechnology company with PepMetics Technology, a proprietary drug discovery platform. PepMetics Molecules are designed to mimic α-helix or β-turn peptides using unique, stable scaffolds.

PRISM BioLab Co., Ltd.

PRISM BioLab BLOG Update! (2023/1/20)

Technology integration: From Cyclic Peptides to Small Molecules

Novel technologies and strategies bring up beautiful sprouts of innovation. In our recent paper1, a two-step strategy for designing a small molecule was demonstrated by collaboration with GeneFrontier through the integration of respective technologies. This is a fantastic example of synergy creation, leveraging each strength to develop a new and practical strategy.

More...

https://lnkd.in/dRBGHvjV

PRISM BioLab BLOG Update! (2022/12/20)

"Targeting PPI: What’s PPI inhibitor?"

PPI-targeted drug discovery strategy is intriguing field. Target identification and functional modulation are crucial for new drug discovery and development. Assay development, technological improvements of structural biology and bioinformatics allowed us to rapidly identify the target so far, even though there are still challenges. Target-based drug discovery is a current standard, and a project often starts with obvious target protein or other biomolecules. It is one of our goals to establish a clearcut strategy and methodology for PPI-targeted drug discovery.

More...
https://lnkd.in/gn78AR_J
#drugdiscovery  #ppi #prismbiolab

PRISM BioLab BLOG Update! (2022/12/16)

"What’s PPI? Introduction to Protein-Protein Interaction"

PRISM is open to all levels of scientific discussion. Our scientists would love to speak with you!

https://lnkd.in/ga7t5AYB

#drugdiscovery #ppi #prismbiolab

PRISM BioLab BLOG Update! (2022/11/16)

Cyclic peptides: Not Just A Goldmine for PPI Drug Discovery

PRISM is open to all levels of scientific discussion. Our scientists would love to speak with you! 

https://lnkd.in/g8dSzHXn

#drugdiscovery #ppi #prismbiolab

【Webinerのお知らせ】Followed by English translation

ファーマインテリジェンス・アワード・ジャパン2022受賞記念ウェビナー『低分子によるPPI阻害：新たな創薬パラダイム』のお知らせ

PRISM BioLabの独自創薬プラットフォームであるPepMetics®は、ペプチドを模倣する独自の骨格をもつ低分子によりタンパク質間相互作用の制御を可能にする技術で、新たな創薬パラダイムを創出する可能性があります。

今回のウェビナーでは、PRISM BioLabの竹原大・代表取締役が、PepMetics®技術の紹介に加え、新たな創薬パラダイムの実現に向けた多くのグローバル製薬企業との連携の状況、パートナーリング、資金調達や組織運営などバイオベンチャー経営の経験談をお話しします。

【概要】
開催日時　：2022年11月9日（水）16:00～17:00
開催形式　：オンライン（Zoom）
言　語 ：日本語
参加費 ：無料
お申し込み：https://lnkd.in/g9iSqZHn

====
Pharma Intelligence Award Japan 2022 Commemorative Webinar "PPI Inhibition by Small Molecules: A New Drug Discovery Paradigm"

PRISM BioLab's proprietary drug discovery platform, PepMetics®, is a technology that enables the control of protein-protein interactions by small molecules with a unique peptide-mimicking backbone, potentially creating a new drug discovery paradigm.

In this webinar, Dai Takehara, President of PRISM BioLab, will introduce the PepMetics® technology and share his experiences in managing a biotech startup, including the status of collaboration with many global pharmaceutical companies, partnering, fundraising and organizational management to realize a new drug discovery paradigm. 

【Outline】
Date & Time ： November 9, 2022 (Wed.) 16:00-17:00 JST
Format ：Online (Zoom)
Language: Japanese
Participation Fee: Free of charge
Registration: https://lnkd.in/g9iSqZHn

PRISM Biolab BLOG Update!

PepMetics®: Our Engine for Paradigm Shifts on PPI Drug Discovery

PRISM is open to all levels of scientific discussion. Our scientists would love to speak with you!

https://lnkd.in/ebv7fDdt

ESMO 2022 is starting tomorrow. Come by our booth 263 to find out how we target undruggable targets with our small molecule peptide mimetics. https://prismbiolab.com
#drugdiscovery #peptides #peptidemimetics #undruggable

Visit PRISM BioLab Co., Ltd. BioLab team at booth 263 at ESMO 2022 conference to find out how we target undruggable targets with our small molecule peptide mimetics. https://prismbiolab.com
#peptides #peptidemimetics #undruggable

Euro

Amazon

Senior Business Advisor

Ivan Plavec

Morita Kohei

Outside Director

Tajima Teruhisa

Part-time auditor

Takehara Dai

Representative Director

Koji Hiroyuki

Chief Executive Officer

Mitsukuchi Hisashi

Outside directorship

Japan Companies With Fewer Than 100 Employees (Top 10K)

Biotechnology Late Stage Companies With Less Than $500M in Revenue

Asia-Pacific (APAC) Late Stage Companies With More Than 10 Employees

Asia-Pacific (APAC) Companies With Fewer Than 50 Employees (Top 10K)

PRISM provider of a therapeutic treatment for non-oncology indications.The company develops therapeutic agents that are used to cure pulmonary fibrosis, cancer and incurable diseases.

Series C - Prism BioLab

Eisai

Venture Round - Prism BioLab

DBJ Capital

Innovation Network Corporation of Japan

Fujisawa

Kanagawa

Japan

Asia

Prism BioLab

PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target

PRISM BioLab Raises 1.5 Billion Yen in Series C Funding

PRISM BioLab raises 1.5 billion yen in Series C fundraising to advance technologies and programs targeting protein-protein interactions

PRISM BioLab raises 1.5 billion yen in Series C fundraising to advance technologies and programs targeting protein ...

United States

North America

A biotechnology company focusing on therapeutic treatment for non-oncology indications.

PRISM Pharma

A leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets.

PRISM BioLab, Co. Ltd.

PRISM BioLab is a biotechnology company focused on developing small molecule drug discovery technology, with a proprietary platform called PepMetics Technology. The company aims to transform 'undruggable' targets to 'druggable' and has two clinical-stage programs for cancer and fibrosis licensed to Japanese pharmaceutical companies.

Board of Director, Head of Research and Development

Advisor, SPARK Translational Medicine

Director, Translational Research Department

Director, Head of Global Research Strategy/Head of RaQualia Pharma Inc. US, Discovery Research

Director, Head of Biology, Discovery Research

Researcher, Discovery Research

Designated Professor, Department of Pharmacology, RIeM

Designated Associate Professor, Department of Pharmacology, RIeM

Research Investigator

Lab Head, Research

Researcher, Research

Post Doc

Hyi-Man Park

President & CEO

Member of the Board

Partner

Manager

http://www.prismbiolab.com/ at PRISM BioLab Corporation

Dai Takehara

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Feb 13, 2024 12:14 PM	296b6bff
public peers	general	Oct 2, 2024 1:59 PM	45696ff5
news daily refresh	general	Sep 1, 2024 6:20 PM	ffa9f190
news processing daily refresh	general	Sep 2, 2024 3:17 PM	8163c42e
news impact assignment daily	general	Sep 2, 2024 9:41 PM	a5c1a4d6
news processing basic	general	Feb 13, 2024 12:14 PM	cde0a67a
company summary	general	Aug 30, 2024 1:30 PM	2c25c42a
signals	general	Oct 2, 2024 1:59 PM	5c6ea0e0
crunchbase trigger	general	Oct 28, 2024 1:50 PM	28596b9c
crunchbase profile	general	Oct 28, 2024 1:54 PM	f54b3012
li profile	general	Feb 13, 2024 12:14 PM	0b08f140
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	d102c987
peers	general	Oct 2, 2024 1:59 PM	cd70b4de
news basic	general	Oct 2, 2024 1:59 PM	01ea84b8
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:PRISMBIOLAB

PRISM BioLab